The precision diagnostics market in Middle East & Africa is expected to grow from US$ 3,152.33 million in 2022 to US$ 6,062.61 million by 2028. It is estimated to grow at a CAGR of 11.5% from 2022 to 2028.
The precision medicine concept is being applied robustly in caring for rare diseases. Although it is more popular in oncology, it is gradually spreading to other specialties. The rising prevalence of cancer and the growing incidence of rare neurological disorders are increasing the demand for precision medicine, driving the growth of the precision diagnostics market. In addition, the rising demand for treatment procedures in oncology and other disorders is surging the adoption of treatment procedures. The genetic test is helpful in many areas of medicine as it identifies mutations or variants in the DNA. Genetic testing, for example, provides information about the risk of developing cancer and diagnose genetic conditions, such as Fragile X syndrome or Huntington's disease.
Based on the type of cancer, genomic cancer testing helps to create more personalize cancer treatment and care plans by helping patients and doctors better understand the diagnosis and reveal specific cancer drivers and market players encourage genomic cancer testing from the beginning of a diagnosis so precision medicine can be administered earlier in the treatment procedure. Thus, early diagnosis can help to promote early and optimal management of the disorders.
Moreover, the growing number of strategic collaborations between biopharmaceutical companies, to develop medicines targeted to treat a specific group of patients based on their particular needs and to provide effective treatment procedures and services, is increasing the number of clinical trials. The factors mentioned above are driving the precision diagnostics market growth.
The precision medicine concept is being applied robustly in caring for rare diseases. Although it is more popular in oncology, it is gradually spreading to other specialties. The rising prevalence of cancer and the growing incidence of rare neurological disorders are increasing the demand for precision medicine, driving the growth of the precision diagnostics market. In addition, the rising demand for treatment procedures in oncology and other disorders is surging the adoption of treatment procedures. The genetic test is helpful in many areas of medicine as it identifies mutations or variants in the DNA. Genetic testing, for example, provides information about the risk of developing cancer and diagnose genetic conditions, such as Fragile X syndrome or Huntington's disease.
Based on the type of cancer, genomic cancer testing helps to create more personalize cancer treatment and care plans by helping patients and doctors better understand the diagnosis and reveal specific cancer drivers and market players encourage genomic cancer testing from the beginning of a diagnosis so precision medicine can be administered earlier in the treatment procedure. Thus, early diagnosis can help to promote early and optimal management of the disorders.
Moreover, the growing number of strategic collaborations between biopharmaceutical companies, to develop medicines targeted to treat a specific group of patients based on their particular needs and to provide effective treatment procedures and services, is increasing the number of clinical trials. The factors mentioned above are driving the precision diagnostics market growth.
Middle East & Africa Precision Diagnostics Market Segmentation
The Middle East & Africa precision diagnostics market is segmented by type, application, end user, and country.- Based on type, the market is segmented into genetic tests, esoteric tests, and others. The genetic tests segment dominated the market in 2022.
- Based on application, the market is fragmented into oncology, cardiology, immunology, respiratory diseases, and others. The oncology segment dominated the market in 2022.
- Based on end user, the market is segmented into hospitals, clinical laboratories, home care, and others. The clinical laboratories segment dominated the market in 2022.
- Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Further, Saudi Arabia dominated the market in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Precision Diagnostics Market - Market Landscape
5. MEA Precision Diagnostics Market - Key Market Dynamics
6. Precision Diagnostics Market- MEA Analysis
7. MEA Precision Diagnostics Market- by Type
8. MEA Precision Diagnostics Market- by Application
9. MEA Precision Diagnostics Market- by End User
10. MEA Precision Diagnostics Market- by Country
11. MEA Precision Diagnostics Market -Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Bayer AG
- Koninklijke Philips N.V.
- Novartis AG
- QIAGEN
- Quest Diagnostics Incorporated
- Sanofi
- Siemens Healthineers AG
- Swiss Precision Diagnostics GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 133 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 3152.33 Million |
| Forecasted Market Value ( USD | $ 6062.61 Million |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Africa, Middle East |
